Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigator-sponsored trial of NKX-019 in Myasthenia gravis

Next Previous
Search
Trial Profile

An Investigator-sponsored trial of NKX-019 in Myasthenia gravis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NKX 019 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Apr 2025 New trial record
    • 26 Mar 2025 According to Nkarta Therapeutics media release, the IND for this investigator-sponsored trial (IST) of NKX019 has been cleared in December 2024, for the treatment of myasthenia gravis (MG) led by researchers at the University of California, Irvine and the University of Kansas Medical Center.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top